Guest Columns & From The Editor

  1. A Technology Roadmap For Today’s Gene Therapy Manufacturing Challenges
    4/18/2019

    In Nov. 2018, The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) published technology roadmaps addressing needs and gaps in three key product areas: gene therapy, antibody-dug conjugates, and vaccines. The roadmaps were developed with the collaborative input of industry, academic, and government experts. This piece highlights technology opportunities for gene therapy manufacturing.

  2. Toward A More Robust Regenerative Medicine Regulatory Pathway
    4/11/2019

    In recent months, the U.S. Food and Drug Administration has increased its compliance focus on the regenerative medicine industry, vowing to crack down on illicit stem cell clinics and others advertising the untested use of human cell and tissue-based products (HCT/P), many of which are used in orthopedics.

  3. What Investors Want: 7 Key Components To Raising Capital
    4/9/2019

    ARM’s 2019 Cell & Gene Therapy Investor Day featured expert-led panels to help the audience wrap their minds around the investment outlook for the cell and gene therapy space. One such panel, aptly titled, “The Investment Outlook for the Cell and Gene Space,” was comprised of investors from DEFTA Partners, Roivant Sciences, Aisling Capital, and Aquilo Capital Management. Dr. Reni Benjamin, Managing Director, Biotechnology Equity Research at Raymond James & Associates moderated the panel.

  4. CDMO Selection: 3 Questions To Save Time And Reduce Stress When Reviewing An MSA
    4/9/2019

    Whether because of unfamiliarity or lack of resources, master service or supply agreement (MSA) and Supply Agreement execution can be time consuming and difficult. At any given pharma company in the development or clinical stage, the leadership team and investors prioritize patients, therapies, and trial results.

  5. Refrigerated Transport For Gene Therapy Products — Exploring The Pros And Cons
    4/5/2019

    The viability and cell count of immunotherapies are extremely sensitive to temperature. Additionally, these products demonstrate reactivity to cooling and thawing rates between room temperature and refrigerated/frozen temperatures.1 The same sensitivity applies to apheresis material, which is susceptible to failure if not fully protected against temperature fluctuations.

  6. ARM’s Lambert Recaps 2019 Cell And Gene Investor Day
    3/29/2019

    ARM’s 2019 Cell and Gene Investor Day took place on March 21st in New York, NY. Now in its seventh year, Investor Day provides insight into financing opportunities for cell and gene therapy-based treatment and tools. I caught up with ARM’s CEO and Cell & Gene Editorial Advisory Board member, Janet Lambert, after the event to discuss top takeaways, near-term financing opportunities, and more.

  7. 4 Strategies For Success In The CAR-T 2.0 Marketplace
    3/27/2019

    As the second wave of CAR-T therapies begins coming to market in the next five years, their manufacturers will need to anticipate and prepare to address many of the same commercial challenges as their predecessors, as well as several additional ones.

  8. Cryogenic Transport For Gene Therapy Products — The Pros And Cons
    3/21/2019

    Temperature-controlled packages used for the transport of gene therapy products use a combination of thermal insulators or thermoregulators to decrease the heat transfer rate from outside of the shipper to the inside. The overall design of the package is pivotal in achieving the minimal heat transfer rate.

  9. ARM’s Cell & Gene Investor Day 2019
    3/20/2019

    Today, March 21st, is ARM’s 7th Annual Cell & Gene Investor Day. The New York City-based one-day event provides institutional, strategic, and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.

  10. 3 Business Challenges from the CDMO’s Perspective
    3/13/2019

    Partnering with a CDMO that marries innovation with technical, regulatory, and manufacturing experience can be cell therapy and gene therapy companies’ best opportunity for scalability and yet their biggest hurdle. From process development through commercial supply and all the steps in between, cell and gene therapy companies expect CDMOs to meet an understandably high bar.